DK1753427T3 - Anvendelse af substituerede quinolinderivater til behandling af lægemiddelresistente mykobakteriesygdomme - Google Patents

Anvendelse af substituerede quinolinderivater til behandling af lægemiddelresistente mykobakteriesygdomme

Info

Publication number
DK1753427T3
DK1753427T3 DK05743054T DK05743054T DK1753427T3 DK 1753427 T3 DK1753427 T3 DK 1753427T3 DK 05743054 T DK05743054 T DK 05743054T DK 05743054 T DK05743054 T DK 05743054T DK 1753427 T3 DK1753427 T3 DK 1753427T3
Authority
DK
Denmark
Prior art keywords
quinoline derivatives
substituted quinoline
treat drug
mycobacterial diseases
resistant mycobacterial
Prior art date
Application number
DK05743054T
Other languages
Danish (da)
English (en)
Inventor
Koenraad Jozef Lodewij Andries
Gestel Jozef Frans Elisabe Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1753427(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1753427T3 publication Critical patent/DK1753427T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05743054T 2004-05-28 2005-05-24 Anvendelse af substituerede quinolinderivater til behandling af lægemiddelresistente mykobakteriesygdomme DK1753427T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102402 2004-05-28
PCT/EP2005/052371 WO2005117875A1 (en) 2004-05-28 2005-05-24 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Publications (1)

Publication Number Publication Date
DK1753427T3 true DK1753427T3 (da) 2008-07-21

Family

ID=34929150

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05743054T DK1753427T3 (da) 2004-05-28 2005-05-24 Anvendelse af substituerede quinolinderivater til behandling af lægemiddelresistente mykobakteriesygdomme

Country Status (34)

Country Link
US (2) US20070249667A1 (enExample)
EP (1) EP1753427B1 (enExample)
JP (2) JP5081617B2 (enExample)
KR (2) KR20130024969A (enExample)
CN (2) CN1976704B (enExample)
AP (1) AP2037A (enExample)
AR (1) AR049127A1 (enExample)
AT (1) ATE390925T1 (enExample)
AU (1) AU2005249231B2 (enExample)
BR (1) BRPI0510414B1 (enExample)
CA (1) CA2566544C (enExample)
CL (1) CL2009001980A1 (enExample)
CY (1) CY1110388T1 (enExample)
DE (1) DE602005005810T2 (enExample)
DK (1) DK1753427T3 (enExample)
EA (1) EA010651B1 (enExample)
ES (1) ES2306146T3 (enExample)
HR (1) HRP20080307T3 (enExample)
IL (1) IL179630A (enExample)
JO (1) JO2524B1 (enExample)
ME (1) ME01105B (enExample)
MX (1) MXPA06013888A (enExample)
MY (1) MY140611A (enExample)
NO (1) NO338624B1 (enExample)
NZ (1) NZ550840A (enExample)
PA (1) PA8635201A1 (enExample)
PL (1) PL1753427T3 (enExample)
PT (1) PT1753427E (enExample)
RS (1) RS50585B (enExample)
SI (1) SI1753427T1 (enExample)
TW (1) TWI363625B (enExample)
UA (1) UA90267C2 (enExample)
WO (1) WO2005117875A1 (enExample)
ZA (1) ZA200609899B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
CA2612614C (en) * 2005-06-28 2017-07-25 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
AU2010292148A1 (en) * 2009-09-11 2012-04-12 Vertex Pharmaceuticals Incorporated Compositions of N-benzyl-3-(4-chlorophenyl)-2- [methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl) acetyl]amino]-N- [3-(4-pyridyl)-1-[2-[4-pyridyl)ethy]propyl]propanamide and uses thereof
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
US9133167B2 (en) 2012-04-27 2015-09-15 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
KR102110366B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CA2954872C (en) * 2014-07-14 2019-08-13 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
CN114129526A (zh) 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
US10196360B2 (en) 2015-10-20 2019-02-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of bedaquiline fumarate and preparation methods therefor
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
EA201891644A1 (ru) * 2016-03-07 2019-04-30 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Антибактериальные соединения и их применение
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
EP3677687A4 (en) * 2017-09-01 2021-05-26 The Kitasato Institute NEW COMPOSITION WITH THERAPEUTIC EFFECT AGAINST INFECTIONS DUE TO THE MYCOBACTERIUM-AVIUM COMPLEX AND THE PROCESS FOR THEIR PRODUCTION
WO2020047596A1 (en) * 2018-09-04 2020-03-12 Monash University Antibacterial compounds and methods of use
KR20210113628A (ko) 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
CN115380029B (zh) * 2019-11-26 2025-06-17 南洋理工大学 用于治疗结核病的化合物
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
CN117050006B (zh) * 2022-05-13 2026-02-13 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023227123A1 (zh) * 2022-05-27 2023-11-30 广州嘉越医药科技有限公司 吡啶衍生物的用途
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
AU2023382389A1 (en) * 2022-11-15 2025-05-15 Eli Lilly And Company Ahr agonists
CN121941498A (zh) 2023-09-28 2026-04-28 詹森药业有限公司 用于治疗非结核分枝杆菌的atp合酶抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399558A (en) * 1993-11-24 1995-03-21 Pathogenesis Corporation Isoflavonoid antibacterial compounds, compositions and use
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
PT1527050E (pt) * 2002-07-25 2010-06-22 Janssen Pharmaceutica Nv Derivados de quinolina e sua utilização como inibidores de micobactérias
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained

Also Published As

Publication number Publication date
CY1110388T1 (el) 2015-04-29
JP2012229239A (ja) 2012-11-22
US20100168133A1 (en) 2010-07-01
IL179630A (en) 2011-05-31
JP2008500992A (ja) 2008-01-17
JP5675718B2 (ja) 2015-02-25
BRPI0510414A (pt) 2007-10-23
ES2306146T3 (es) 2008-11-01
TWI363625B (en) 2012-05-11
EA010651B1 (ru) 2008-10-30
DE602005005810D1 (de) 2008-05-15
KR101371653B1 (ko) 2014-03-07
NO20066041L (no) 2007-02-27
IL179630A0 (en) 2007-07-04
WO2005117875A1 (en) 2005-12-15
AP2006003828A0 (en) 2006-12-31
CN1976704A (zh) 2007-06-06
JO2524B1 (en) 2010-03-17
NO338624B1 (no) 2016-09-19
UA90267C2 (ru) 2010-04-26
CN102908347A (zh) 2013-02-06
EP1753427A1 (en) 2007-02-21
TW200608974A (en) 2006-03-16
AU2005249231A1 (en) 2005-12-15
DE602005005810T2 (de) 2009-04-09
KR20130024969A (ko) 2013-03-08
ME01105B (me) 2013-03-20
ZA200609899B (en) 2009-01-28
SI1753427T1 (sl) 2008-10-31
NZ550840A (en) 2010-01-29
AP2037A (en) 2009-10-09
BRPI0510414B1 (pt) 2022-04-05
HK1106136A1 (en) 2008-03-07
MY140611A (en) 2009-12-31
US20070249667A1 (en) 2007-10-25
AR049127A1 (es) 2006-06-28
EA200602260A1 (ru) 2007-04-27
KR20070017393A (ko) 2007-02-09
RS50585B (sr) 2010-05-07
PT1753427E (pt) 2008-07-04
MXPA06013888A (es) 2007-01-26
EP1753427B1 (en) 2008-04-02
CN1976704B (zh) 2012-12-05
PA8635201A1 (es) 2006-05-16
PL1753427T3 (pl) 2008-09-30
CA2566544C (en) 2012-04-17
ATE390925T1 (de) 2008-04-15
CL2009001980A1 (es) 2010-04-16
AU2005249231B2 (en) 2010-11-11
CA2566544A1 (en) 2005-12-15
HRP20080307T3 (hr) 2008-07-31
JP5081617B2 (ja) 2012-11-28

Similar Documents

Publication Publication Date Title
CY2022001I1 (el) Παραγωγα του uk-2a
CY2013035I1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DK1720866T3 (da) Fremgangsmåde
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DK1830850T3 (da) Quinolin-derivater til behandling af latent tuberkulose
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK1791820T3 (da) Enantioselektiv fremstilling af quinolinderivater
EP2035001A4 (en) STABLE LAQUINIMOD PREPARATIONS
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
DE602005016890D1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
ATE496029T1 (de) Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
HRP20150962T1 (xx) Postupak za pripremu atazanavir bisulfata i novih oblika
ITMI20041869A1 (it) Nuovi inibitori delle istone deacetilasi
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
CR9144A (es) Formulaciones de benzoxazoles sustituidos
NO20043305D0 (no) Preparation of lodixanol
DK1831605T3 (da) Fremgangsmåde vedrørende forbrænding
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas